Protalix Biotherapeutics, Inc. (PLX)
2.53
+0.05
(+2.02%)
USD |
NYAM |
Aug 27, 09:33
Protalix Biotherapeutics Net Income (Quarterly) : 3.777M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.777M |
| March 31, 2026 | 18.32M |
| December 31, 2025 | -5.504M |
| September 30, 2025 | 2.355M |
| June 30, 2025 | 0.164M |
| March 31, 2025 | -3.619M |
| December 31, 2024 | 6.494M |
| September 30, 2024 | 3.236M |
| June 30, 2024 | -2.203M |
| March 31, 2024 | -4.595M |
| December 31, 2023 | -6.044M |
| September 30, 2023 | -1.852M |
| June 30, 2023 | 19.34M |
| March 31, 2023 | -3.131M |
| December 31, 2022 | -3.74M |
| September 30, 2022 | -3.567M |
| June 30, 2022 | -5.334M |
| March 31, 2022 | -2.286M |
| December 31, 2021 | -6.667M |
| September 30, 2021 | -4.199M |
| June 30, 2021 | -11.24M |
| March 31, 2021 | -5.475M |
| December 31, 2020 | 0.397M |
| September 30, 2020 | -4.437M |
| June 30, 2020 | -4.15M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.667M |
| December 31, 2019 | 0.291M |
| September 30, 2019 | -3.56M |
| June 30, 2019 | -7.743M |
| March 31, 2019 | -7.264M |
| December 31, 2018 | -5.434M |
| September 30, 2018 | -5.322M |
| June 30, 2018 | -8.462M |
| March 31, 2018 | -9.40M |
| December 31, 2017 | -15.14M |
| September 30, 2017 | -11.44M |
| June 30, 2017 | 0.45M |
| March 31, 2017 | -59.15M |
| December 31, 2016 | -2.624M |
| September 30, 2016 | -7.29M |
| June 30, 2016 | -10.74M |
| March 31, 2016 | -8.526M |
| September 30, 2015 | -3.82M |
| June 30, 2015 | -5.071M |
| March 31, 2015 | -5.972M |
| December 31, 2014 | -8.469M |
| September 30, 2014 | -8.01M |
| June 30, 2014 | -6.119M |
| March 31, 2014 | -7.345M |
| December 31, 2013 | -10.88M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Altimmune, Inc. | -22.82M |
| Taysha Gene Therapies, Inc. | -46.64M |
| Humacyte, Inc. | -36.80M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 19.90M |
| Total Expenses (Quarterly) | 16.12M |
| EPS Diluted (Quarterly) | 0.0458 |
| Enterprise Value | 167.65M |
| Gross Profit Margin (Quarterly) | 60.99% |
| Profit Margin (Quarterly) | 18.98% |
| Earnings Yield | 8.98% |
| Operating Earnings Yield | 11.27% |
| Normalized Earnings Yield | 8.972 |